NEUROCRINE BIOSCIENCES INC Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent
NEUROCRINE BIOSCIENCES INC (NBIX) reported Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent of -$600.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent · last filed 2026-07-31
- NEUROCRINE BIOSCIENCES INC other comprehensive income (loss), foreign currency translation adjustment, tax, portion attributable to parent for the quarter ending 2026-06-30 was -$600.00K.
- NEUROCRINE BIOSCIENCES INC other comprehensive income (loss), foreign currency translation adjustment, tax, portion attributable to parent for the quarter ending 2026-03-31 was $0.00.
- NEUROCRINE BIOSCIENCES INC other comprehensive income (loss), foreign currency translation adjustment, tax, portion attributable to parent for the quarter ending 2025-12-31 was $100.00K, a 97.22% decline year-over-year.
- NEUROCRINE BIOSCIENCES INC other comprehensive income (loss), foreign currency translation adjustment, tax, portion attributable to parent for the quarter ending 2025-09-30 was -$1.60M.
- NEUROCRINE BIOSCIENCES INC other comprehensive income (loss), foreign currency translation adjustment, tax, portion attributable to parent for fiscal 2025 was -$3.80M, a 445.45% decline from fiscal 2024.
- NEUROCRINE BIOSCIENCES INC other comprehensive income (loss), foreign currency translation adjustment, tax, portion attributable to parent for fiscal 2024 was $1.10M.
- NEUROCRINE BIOSCIENCES INC other comprehensive income (loss), foreign currency translation adjustment, tax, portion attributable to parent for fiscal 2023 was -$2.40M.
- NEUROCRINE BIOSCIENCES INC other comprehensive income (loss), foreign currency translation adjustment, tax, portion attributable to parent for fiscal 2022 was -$2.90M.
| Period end | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$600.00K 10-Q · filed 2026-07-31 | -$600.00K 10-Q · filed 2026-07-31 | -$500.00K derived: sum of 3 quarters · filed 2026-07-31 | -$2.10M derived: sum of 4 quarters · filed 2026-07-31 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-05 | $100.00K derived: sum of 2 quarters · filed 2026-05-05 | -$1.50M derived: sum of 3 quarters · filed 2026-05-05 | -$2.30M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | -$1.50M derived: sum of 2 quarters · filed 2026-02-11 | -$2.30M derived: sum of 3 quarters · filed 2026-07-31 | -$3.80M 10-K · filed 2026-02-11 |
| 2025-09-30 | -$1.60M 10-Q · filed 2025-10-28 | -$2.40M derived: sum of 2 quarters · filed 2026-07-31 | -$3.90M 10-Q · filed 2025-10-28 | -$300.00K derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-06-30 | -$800.00K 10-Q · filed 2026-07-31 | -$2.30M 10-Q · filed 2026-07-31 | $1.30M derived: sum of 3 quarters · filed 2026-07-31 | -$1.60M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-03-31 | -$1.50M 10-Q · filed 2026-05-05 | $2.10M derived: sum of 2 quarters · filed 2026-05-05 | -$800.00K derived: sum of 3 quarters · filed 2026-05-05 | -$900.00K derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $3.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $700.00K derived: sum of 2 quarters · filed 2026-02-11 | $600.00K derived: sum of 3 quarters · filed 2026-02-11 | $1.10M 10-K · filed 2026-02-11 |
| 2024-09-30 | -$2.90M 10-Q · filed 2025-10-28 | -$3.00M derived: sum of 2 quarters · filed 2025-10-28 | -$2.50M 10-Q · filed 2025-10-28 | -$4.20M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-06-30 | -$100.00K 10-Q · filed 2025-07-30 | $400.00K 10-Q · filed 2025-07-30 | -$1.30M derived: sum of 3 quarters · filed 2026-02-11 | $100.00K derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-03-31 | $500.00K 10-Q · filed 2025-05-05 | -$1.20M derived: sum of 2 quarters · filed 2026-02-11 | $200.00K derived: sum of 3 quarters · filed 2026-02-11 | -$700.00K derived: sum of 4 quarters · filed 2026-02-11 |
| 2023-12-31 | -$1.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | -$300.00K derived: sum of 2 quarters · filed 2026-02-11 | -$1.20M derived: sum of 3 quarters · filed 2026-02-11 | -$2.40M 10-K · filed 2026-02-11 |
| 2023-09-30 | $1.40M 10-Q · filed 2024-10-30 | $500.00K derived: sum of 2 quarters · filed 2024-10-30 | -$700.00K 10-Q · filed 2024-10-30 | -$3.60M derived: sum of 4 quarters · filed 2025-02-10 |
| 2023-06-30 | -$900.00K 10-Q · filed 2024-08-01 | -$2.10M 10-Q · filed 2024-08-01 | -$5.00M derived: sum of 3 quarters · filed 2025-02-10 | -$5.00M derived: sum of 4 quarters · filed 2025-02-10 |
| 2023-03-31 | -$1.20M 10-Q · filed 2024-05-01 | -$4.10M derived: sum of 2 quarters · filed 2025-02-10 | -$4.10M derived: sum of 3 quarters · filed 2025-02-10 | -$4.10M derived: sum of 4 quarters · filed 2025-02-10 |
| 2022-12-31 | -$2.90M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-10 | -$2.90M derived: sum of 2 quarters · filed 2025-02-10 | -$2.90M derived: sum of 3 quarters · filed 2025-02-10 | -$2.90M 10-K · filed 2025-02-10 |
| 2022-09-30 | $0.00 10-Q · filed 2023-10-31 | $0.00 derived: sum of 2 quarters · filed 2023-10-31 | $0.00 10-Q · filed 2023-10-31 | |
| 2022-06-30 | $0.00 10-Q · filed 2023-08-01 | $0.00 10-Q · filed 2023-08-01 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-03 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-02-09 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |